Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry.
Por:
Siniscalchi C, Suriñach JM, Visonà A, Fernández-Reyes JL, Gómez-Cuervo C, Verhamme P, Marchena P, Farge-Bancel D, Moisés J, Monreal M and and the RIETE Investigators
Publicada:
17 sep 2020
Ahead of Print:
17 sep 2020
Resumen:
Introduction We previously reported that during the course of anticoagulation for venous thromboembolism (VTE) patients using statins were at a lower risk to die than nonusers. Methods We used the R egistro I nformatizado E nfermedad T rombo E mbólica (RIETE) registry to validate our previous findings in a subsequent cohort of patients and to compare the risk of death according to the use of different types of statins. Results From January 2018 to December 2019, 19,557 patients with VTE were recruited in RIETE. Of them, 4,065 (21%) were using statins (simvastatin, 1,406; atorvastatin, 1,328; rosuvastatin, 246; and others, 1,085). During anticoagulation (192 vs.182 days, for statin and no statin users respectively), 500 patients developed a VTE recurrence, 519 suffered major bleeding, and 1,632 died (fatal pulmonary embolism [PE], 88 and fatal bleeding, 78). On multivariable analysis, statin users were at a lower risk to die (hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.59-0.79) than nonusers. When separately analyzing the drugs, on multivariable analysis, patients using simvastatin (HR = 0.64; 95% CI: 0.52-0.80), atorvastatin (HR 0.72; 95% CI: 0.58-0.89), or other statins (HR = 0.67; 95% CI: 0.52-0.87) were at a lower risk to die than nonusers. For those using rosuvastatin, difference was not statistically significant (HR = 0.77; 95% CI: 0.50-1.19), maybe due to the sample size. Conclusion Our data validate previous findings and confirm that VTE patients using statins at baseline are at a lower risk to die than nonusers. No statistically differences were found according to type of statins.
Filiaciones:
Siniscalchi C:
Department of Internal and Emergency Medicine, Angiology Unit, Parma University Hospital, Parma, Italy
Suriñach JM:
Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain
Visonà A:
Department of Vascular Medicine, Ospedale Castelfranco Veneto, Castelfranco Veneto, Italy
Fernández-Reyes JL:
Department of Internal Medicine, Complejo Hospitalario de Jaén, Jaén, Spain
Gómez-Cuervo C:
Department of Internal Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain
Verhamme P:
Vascular Medicine and Haemostasis, University of Leuven, Leuven, Belgium
Marchena P:
Department of Internal Medicine and Emergency, Parc Sanitari Sant Joan de Déu-Hospital General, Barcelona, Spain
Farge-Bancel D:
Department of Internal Medicine and Pathology, Hôpital Saint-Louis, Paris, France
Moisés J:
Department of Pneumonology, Hospital Universitario Clínic de Barcelona, Barcelona, Spain
Monreal M:
Department of Internal Medicine, Hospital Germans Trias i Pujol, Badalona, Barcelona, Universidad Católica de Murcia, Spain
Open Access
|